For Akebia Therapeutics Inc. [AKBA], Analyst sees a rise to $8. What next?

Related

Akebia Therapeutics Inc. [NASDAQ: AKBA] loss -3.49% or -0.08 points to close at $2.21 with a heavy trading volume of 2713416 shares. The company report on January 10, 2022 that Akebia Therapeutics to Present at H.C. Wainwright Bioconnect Conference.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that David Spellman, Chief Financial Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will take place virtually January 10-13, 2022.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


An audio replay of the fireside chat will be available through the Investors section of Akebia’s website at https://ir.akebia.com for approximately 90 days following the conference.

It opened the trading session at $2.29, the shares rose to $2.3281 and dropped to $2.20, the range by which the price of stock traded the whole day. The daily chart for AKBA points out that the company has recorded -33.43% loss over the past six months. However, it is still -2.79% lower than its most recent low trading price.

If we look at the average trading volume of 2.76M shares, AKBA reached to a volume of 2713416 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Akebia Therapeutics Inc. [AKBA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKBA shares is $7.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKBA stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Cantor Fitzgerald have made an estimate for Akebia Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 08, 2021. The new note on the price target was released on January 29, 2021, representing the official price target for Akebia Therapeutics Inc. stock. Previously, the target price had yet another drop from $18 to $15, while Needham kept a Buy rating on AKBA stock. On August 06, 2019, analysts decreased their price target for AKBA shares from 19 to 17.

The Average True Range (ATR) for Akebia Therapeutics Inc. is set at 0.15, with the Price to Sales ratio for AKBA stock in the period of the last 12 months amounting to 1.87. The Price to Book ratio for the last quarter was 2.80, with the Price to Cash per share for the same quarter was set at 1.16.

Trading performance analysis for AKBA stock

Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.34. With this latest performance, AKBA shares dropped by -13.33% in over the last four-week period, additionally sinking by -33.43% over the last 6 months – not to mention a drop of -28.94% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AKBA stock in for the last two-week period is set at 39.25, with the RSI for the last a single of trading hit 38.16, and the three-weeks RSI is set at 40.33 for Akebia Therapeutics Inc. [AKBA]. The present Moving Average for the last 50 days of trading for this stock 2.60, while it was recorded at 2.25 for the last single week of trading, and 2.95 for the last 200 days.

Akebia Therapeutics Inc. [AKBA]: A deeper dive into fundamental analysis

Akebia Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.70.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Akebia Therapeutics Inc. [AKBA]

There are presently around $217 million, or 59.60% of AKBA stock, in the hands of institutional investors. The top three institutional holders of AKBA stocks are: STATE STREET CORP with ownership of 15,856,428, which is approximately 13.207% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 14,052,487 shares of the stock with an approximate value of $31.06 million in AKBA stocks shares; and VANGUARD GROUP INC, currently with $27.43 million in AKBA stock with ownership of nearly 2.102% of the company’s market capitalization.

59 institutional holders increased their position in Akebia Therapeutics Inc. [NASDAQ:AKBA] by around 12,857,380 shares. Additionally, 59 investors decreased positions by around 20,326,884 shares, while 31 investors held positions by with 64,811,128 shares. The mentioned changes placed institutional holdings at 97,995,392 shares, according to the latest SEC report filing. AKBA stock had 11 new institutional investments in for a total of 1,319,622 shares, while 23 institutional investors sold positions of 11,627,476 shares during the same period.